VIVUS Announces AANP Scientific Presentations

VIVUS Announces AANP Scientific Presentations

MOUNTAIN VIEW, Calif., June 21, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc.
(Nasdaq:VVUS), a biopharmaceutical company commercializing and developing
innovative, next-generation therapies to address unmet needs in obesity and
sexual health, today announced the following scientific presentations:

Conference

AANP 2013: American Association of Nurse Practitioners 28^th National
Conference

June 19-23, 2013

The Venetian, The Palazzo, and Sands Expo and Convention Center, Las Vegas,
Nevada

Date/Time

Poster Presentation Date:

  *Poster Presentation: Thursday, June 20, 4:00 PM to 6:00 PM; Friday, June
    21, 4:00 PM to 6:00 PM; Saturday, June 22, 12:30 PM to 2:15 PM
  *Exhibit Hall Hours: Thursday, June 20, 10:45 AM to 1:00 PM; Friday, June
    21, 11:00 AM to 6:00 PM; Saturday, June 22, 11:00 AM to 2:30 PM

Session Location: The Venetian, The Palazzo and Sands Expo and Convention
Center, Exhibit Hall

Presentation Title

Weight Loss With Phentermine and Topiramate Extended-Release in Obese and
Overweight Subjects Over 1 Year

Authors: Pamela A. McCullough, PhD, APRN^a; Donna T. Chow^b; Wesley W. Day,
PhD^b

Affiliations: ^aKentucky Research Group, Louisville, KY; ^bVIVUS, Inc.,
Mountain View, CA

Conference

AANP 2013: American Association of Nurse Practitioners 28^th National
Conference

June 19-23, 2013

The Venetian, The Palazzo, and Sands Expo and Convention Center, Las Vegas,
Nevada

Date/Time

Poster Presentation Date:

  *Poster Presentation: Thursday, June 20, 4:00 PM to 6:00 PM; Friday, June
    21, 4:00 PM to 6:00 PM; Saturday, June 22, 12:30 PM to 2:15 PM
  *Exhibit Hall Hours: Thursday, June 20, 10:45 AM to 1:00 PM; Friday, June
    21, 11:00 AM to 6:00 PM; Saturday, June 22, 11:00 AM to 2:30 PM

Session Location: The Venetian, The Palazzo and Sands Expo and Convention
Center, Exhibit Hall

Presentation Title

Weight Loss and Improvements in Quality of Life Associated With Baseline
Body-Mass Index in Obese and Overweight Patients Treated With
Phentermine/Topiramate Extended-Release

Authors: Timothy Church, MD^a; Ronette L. Kolotkin, PhD^b; Santosh T.
Varghese, MD^c

Affiliations: ^aPennington Biomedical Research Center, Louisiana State
University System, Baton Rouge, LA; ^bDuke University Medical Center and
Obesity and Quality of Life Consulting, Durham, NC; ^cVIVUS, Inc., Mountain
View, CA, USA

Conference

AANP 2013: American Association of Nurse Practitioners 28^th National
Conference

June 19-23, 2013

The Venetian, The Palazzo, and Sands Expo and Convention Center, Las Vegas,
Nevada

Date/Time

Poster Presentation Date:

  *Poster Presentation: Thursday, June 20, 4:00 PM to 6:00 PM; Friday, June
    21, 4:00 PM to 6:00 PM; Saturday, June 22, 12:30 PM to 2:15 PM
  *Exhibit Hall Hours: Thursday, June 20, 10:45 AM to 1:00 PM; Friday, June
    21, 11:00 AM to 6:00 PM; Saturday, June 22, 11:00 AM to 2:30 PM

Session Location: The Venetian, The Palazzo and Sands Expo and Convention
Center, Exhibit Hall

Presentation Title

Prevention of Type 2 Diabetes Mellitus in Subjects With Prediabetes Using
Phentermine and Topiramate Extended-Release for 1 Year

Authors: Miriam M. Rueger, RN, MPH, RD, CDE^a; W. Timothy Garvey, MD^a; Lan T.
Nguyen^b; Craig A. Peterson, MS^b

Affiliations: ^aUniversity of Alabama at Birmingham, Birmingham, AL; ^bVIVUS,
Inc., Mountain View, CA

About Qsymia

Qsymia^® (phentermine and topiramate extended-release) capsules CIV is
approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet
and increased physical activity for chronic weight management in adults with
an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or
greater (overweight) in the presence of at least one weight-related medical
condition such as high blood pressure, type 2 diabetes, or high cholesterol.

The effect of Qsymia on cardiovascular morbidity and mortality has not been
established. The safety and effectiveness of Qsymia in combination with other
products intended for weight loss, including prescription and over-the-counter
drugs, and herbal preparations, have not been established.

Important Safety Information

Qsymia^® (phentermine and topiramate extended-release) capsules CIV is
contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism;
in patients receiving treatment or within 14 days following treatment with
monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to
sympathomimetic amines, topiramate, or any of the inactive ingredients in
Qsymia.

Qsymia can cause fetal harm. Females of reproductive potential should have a
negative pregnancy test before treatment and monthly thereafter and use
effective contraception consistently during Qsymia therapy. If a patient
becomes pregnant while taking Qsymia, treatment should be discontinued
immediately, and the patient should be informed of the potential hazard to the
fetus.

The most commonly observed side effects in controlled clinical studies, 5% or
greater and at least 1.5 times placebo, include paraesthesia, dizziness,
dysgeusia, insomnia, constipation, and dry mouth.

About VIVUS

VIVUS is a biopharmaceutical company commercializing and developing
innovative, next-generation therapies to address unmet needs in obesity and
sexual health. For more information about the company, please visit
www.vivus.com.

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely,"
"may," "plan," "potential," "predict," "opportunity" and "should," among
others. There are a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements. VIVUS does
not undertake an obligation to update or revise any forward-looking
statements. Investors should read the risk factors set forth in VIVUS's Form
10-K for the year ending December 31, 2012, as amended by the Form 10-K/A
filed on April 30, 2013 and by the Form 10-K/A filed on June 12, 2013, and
periodic reports filed with the Securities and Exchange Commission.

CONTACT: VIVUS, Inc.
         Dana B. Shinbaum
         Corporate Development
         & Investor Relations
         shinbaum@vivus.com
        
         Investor Relations:
         The Trout Group
         Brian Korb
         bkorb@troutgroup.com
         646-378-2923